Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates

分组1 - Eton Pharmaceuticals reported quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.12 per share, compared to a loss of $0.02 per share a year ago, representing an earnings surprise of -58.33% [1] - The company posted revenues of $21.28 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.22%, and this is an increase from year-ago revenues of $11.65 million [2] - Eton Pharmaceuticals has topped consensus revenue estimates four times over the last four quarters [2] 分组2 - The stock has added about 12.5% since the beginning of the year, while the S&P 500 has declined by 3.2% [3] - The current consensus EPS estimate for the coming quarter is $0.20 on $21.5 million in revenues, and for the current fiscal year, it is $1.02 on $103.84 million in revenues [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8]